Another trial date has been set for MRI patent litigation filed by MRI vendor Fonar againstGE, Hitachi and several imaging centers. The case is scheduledto go to trial April 10, according to Fonar attorney Ronald Schutzof Robins, Kaplan, Miller and
Another trial date has been set for MRI patent litigation filed by MRI vendor Fonar againstGE, Hitachi and several imaging centers. The case is scheduledto go to trial April 10, according to Fonar attorney Ronald Schutzof Robins, Kaplan, Miller and Ciresi of Minneapolis.
Fonar, of Melville, NY, filed suit against the companies inSeptember, 1992, in U.S. District Court of Eastern New York inHauppauge, NY, claiming that its basic patents for MRI technologyhad been infringed (SCAN 11/23/94). A trial date had been setfor December but was later postponed. Fonar is asking for $362million in damages.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.